HANDOK Inc.

A002390

KR7002390003

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-07-15 pm EDT			5-day change	1st Jan Change
16,260 ^KRW	-0.85%		-7.30%	+13.71%

Jun. 26	WELT Corp., Ltd announced that it has received KRW 14 billion in funding from Envisioning Partners, Korea Development Bank, Investment Arm, Shinhan Venture Investment Co, Ltd., IMM Investment, Corp., HANDOK Inc.	CI
May. 24	Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea	MT

WELT Corp., Ltd announced that it has received KRW 14 billion in funding from Envisioning Partners, Korea Development Bank, Investment Arm, Shinhan Venture Investment Co, Ltd., IMM Investment, Corp., HANDOK Inc.

June 25, 2024

WELT Corp., Ltd announced that it has received KRW 14,000 million in a round of funding led by returning investor, Envisioning Partners on June 26, 2024. The transaction included participation from new investors, Korea Development Bank, Investment Arm, Shinhan Venture Investment Co, Ltd., IMM Investment, Corp., HANDOK Inc. The company has raised a total of KRW 28,000 million funding till date.

Latest news about HANDOK Inc.

WELT Corp., Ltd announced that it has received KRW 14 billion in funding from Envisioning Partners, Korea Development Bank, Investment Arm, Shinhan Venture Investment Co, Ltd., IMM Investment, Corp., HANDOK Inc.	Jun. 25	CI
Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea	May. 24	MT
Biocon Limited Signs Exclusive Licensing and Supply Deal for the Commercialization of Liraglutide in South Korea with Handok Inc	May. 23	CI
Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	Apr. 15	MT
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea	Apr. 14	CI
Sobi to Expand in South Korea via Rare Disease JV with Handok	Feb. 13	MT
HANDOK Inc.(KOSE:A002390) dropped from S&P Global BMI Index	23-09-18	CI
HANDOK Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Rezolute Unveils Plans for Secondary Offering of 3.24 Million Shares	22-10-28	MT
I-Mab Completes Enrollment in China Phase 3 Trial of Eftansomatropin Alfa in Pediatric Growth Hormone Deficiency	22-06-14	MT
AUM Biosciences Enters in A Strategic Collaboration with Handok and CMG Pharm to Develop ‘CHC2014’, New Pan-TRK Inhibitor for Cancer Treatment	21-05-11	CI
WELT Corp., Ltd announced that it has received KRW 6 billion in funding from HANDOK Inc., Smilegate Investment, Inc., POSCO Venture Capital Co., Ltd.	21-03-24	CI
Adicet Bio, Inc. announced that it has received $80 million in funding from a group of investors	19-10-01	CI
Rezolute, Inc. announced that it has received $24.05 million in funding from Genexine, Inc., Handok, Inc., District 2 Capital Fund LP, The Bigger Capital Fund, LP and another investor	19-08-11	CI
Adicet Bio, Inc. announced that it expects to receive $80 million in funding	19-07-24	CI
Rezolute, Inc. announced that it expects to receive $20.25 million in funding from District 2 Capital Fund LP, The Bigger Capital Fund, LP, Genexine, Inc., Handok, Inc.	19-07-22	CI
TRIGR Therapeutics, Inc announced that it has received $14 million in funding from Handok Inc.	19-03-24	CI
BiomX Ltd announced that it has received $32 million in funding from a group of investors	19-02-19	CI
Rezolute, Inc. announced that it has received $25 million in funding from Genexine, Inc., Handok, Inc.	19-01-29	CI
Rezolute, Inc. announced that it expects to receive $25 million in funding from Genexine, Inc., Handok Inc.	19-01-06	CI
An unknown buyer cancelled the acquisition of 2.7% stake in Genexine, Inc. from Handok Inc..	18-12-19	CI
Handok Hires Cho Jeong-yol to replace Kim Chul-joon as President	18-09-05	CI
TRIGR Therapeutics, Inc announced that it expects to receive $9 million in funding from Handok Inc.	18-07-30	CI
An unknown buyer agreed to acquire 2.7% stake in Genexine, Inc. from Handok Inc. for KRW 27.3 billion.	17-12-20	CI
Handok Inc.(KOSE:A002390) added to S&P Global BMI Index	15-09-21	CI

Chart HANDOK Inc.

Duration

Period

More charts

Company Profile

HANDOK Inc. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals. The Company's products include Amaryl for diabetes; Tritace for hypertension, myocardial infarction, heart failure and other cardiovascular diseases; Teveten and Triapin for essential hypertension; Munobal for hypertension and stenocardia; Ketas for disturbance of cerebral circulation; Lasix for hypertension and edema, and remedies for skin and others. It also provides over-the-counter (OTC) pharmaceuticals, healthcare products, as well as medical devices, diagnostic reagents and vaccines. In addition, the Company is involved in the real estates rental business. On July 26, 2013, it changed its name to HANDOK Inc. from Handok Pharmaceuticals Co., LTD.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HANDOK INC.	+13.71%	162M
ELI LILLY AND COMPANY	+61.53%	848B
NOVO NORDISK A/S	+32.90%	627B
JOHNSON & JOHNSON	-3.66%	363B
MERCK & CO., INC.	+15.06%	318B
ABBVIE INC.	+9.18%	299B
ROCHE HOLDING AG	+12.23%	234B
NOVARTIS AG	+16.17%	225B
AMGEN INC.	+15.67%	179B
PFIZER, INC.	+2.47%	167B

Other Pharmaceuticals

HANDOK Inc.

Equities

A002390

KR7002390003

Pharmaceuticals

WELT Corp., Ltd announced that it has received KRW 14 billion in funding from Envisioning Partners, Korea Development Bank, Investment Arm, Shinhan Venture Investment Co, Ltd., IMM Investment, Corp., HANDOK Inc.

Latest news about HANDOK Inc.

Chart HANDOK Inc.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals